一、财务资助基本情况 证券代码：000888 证券简称：峨眉山A 公告编号：2025-44 （一）5000 万元财务资助 峨眉山旅游股份有限公司关于为 为保障"只有峨眉山"剧场演艺项目日常运营，经峨眉山旅 游股份有限公司（以下简称"公司"）2022 年 12 月第五届董事 会第一百二十四次会议、2023 年 1 月第一次临时股东大会表决 通过，同意公司对峨眉山云上旅游投资有限公司（以下简称"云 上旅投"）提供不超过人民币五千万元的财务资助，财务资助期 限以第一个实际提款日起算不超过 6 年，财务资助利率按"同期 中国人民银行贷款基准利率"执行（详见《关于对控股子公司提 供财务资助暨关联交易的公告》，公告编号：2022-61）。为防范 风险，峨眉山旅游投资开发（集团）有限公司、四川旅投航空旅 游有限责任公司就本次财务资助事宜按照出资比例提供连带责 任担保，四川省锦弘集团有限责任公司因正在推进重组整合，不 能对云上旅投作财务担保或财务资助。 控股子公司提供财务资助的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 三、风险提示及公司采取的措施 公司已成立专 ...

证券代码：000736 证券简称：*ST 中地 公告编号：2025-084 债券代码：149610 债券简称：21 中交债 债券代码：148551 债券简称：23 中交 06 债券代码：134164 债券简称：25 中交 01 债券代码：133965 债券简称：25 中交 02 债券代码：134197 债券简称：25 中交 03 中交地产股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示： 作比例以同等条件向武汉嘉秀房地产开发有限公司（以下简称"武汉 嘉秀"）、台州滨交房地产开发有限公司（以下简称"台州滨交"） 提交董事会和股东大会审议。 一、财务资助进展情况概述 （一）简述 按照房地产公司经营惯例及合作约定，公司作为房地产项目公司 股东，与合作方共同为房地产项目公司提供股东借款，满足其日常经 营资金需求，如该房地产项目公司为公司的参股公司或并表但持股未 超过 50%的控股子公司，则上述行为将构成公司对房地产项目公司提 供财务资助。 （二）财务资助基本情况 助不超过 980 万元（到期续借），期限不超过 1 年，年利率 0%。 助合计不 ...

Core Viewpoint - Shenzhen Aishide Co., Ltd. held its 18th (temporary) board meeting on August 5, 2025, where several significant resolutions were passed regarding guarantees for credit lines and financial support for subsidiaries [1][2][4]. Group 1: Resolutions on Guarantees - The company and its subsidiaries plan to apply for a total credit line of RMB 3.5 billion from Apple Computer Trading (Shanghai) Co., Ltd., with cross guarantees provided by the company and its subsidiaries [2][4]. - A resolution was passed to increase the comprehensive credit line application to RMB 250 million from Zheshang Bank Co., Ltd. [5][6]. - The company will provide a guarantee of RMB 2 billion for its subsidiary Shenzhen Shifeng Technology Co., Ltd. to apply for credit from Samsung (China) Investment Co., Ltd. [7][8]. - A guarantee of RMB 450 million will be provided for Shenzhen Koodong Digital Co., Ltd. to apply for credit from Shanghai Ingram Logistics Co., Ltd. [9][10]. - The company plans to provide a guarantee of up to RMB 1.5 billion for its subsidiary Aishide (Hong Kong) Co., Ltd. to meet increasing working capital needs [12][13]. Group 2: Financial Support and Related Transactions - The controlling shareholder and related parties will provide financial support of up to RMB 600 million to the company and its subsidiaries, with a term not exceeding two years [15][16]. - A resolution was passed regarding the acquisition of a 13.6365% stake in a limited partnership, which will enhance the company's investment structure and support the development of invested enterprises [61][62][68]. - The company will hold an extraordinary general meeting on August 21, 2025, to discuss the resolutions passed in the board meeting [25][26].

证券代码：600807 证券简称：济高发展 公告编号：临2025-044 济南高新发展股份有限公司第十一届董事会第二十四次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 公司第十一届董事会第二十四次临时会议于2025年8月1日上午10点，在中国（山东）自由贸易试验区济 南片区经十东路7000号汉峪金融商务中心A4-4号楼11层会议室，以现场和通讯结合方式召开，会议通 知和材料于2025年7月28日以电子通讯方式发出。应出席会议董事9名，实际出席会议董事9名，公司监 事列席了会议，符合《中华人民共和国公司法》等有关法律、行政法规、部门规章、规范性文件和《公 司章程》的规定。会议召集人、主持人为公司董事长王成东先生。 经投票表决，会议形成如下决议： 具体内容详见同日披露的《关于修订〈公司章程〉并取消监事会及修订部分公司治理制度的公告》； 《济南高新发展股份有限公司章程》详见公司将于2025年第三次临时股东大会召开前披露的股东大会会 议材料。 表决结果：9票同意、0票反对、0票弃权。 二、审议通过《关于审议修订〈股 ...

Core Viewpoint - The company plans to provide financial assistance in the form of a loan not exceeding 6 million yuan to its subsidiary, Shandong Aikewei Biotechnology Co., Ltd., for operational needs, with a loan term of one year and interest rates to be determined based on prevailing bank rates and actual financing costs [1][2][7]. Financial Assistance Details - The financial assistance will not affect the company's normal business operations and funding usage [2][7]. - The loan amount is capped at 6 million yuan, with the interest rate to be negotiated at the time of signing the loan agreement [1][7]. - The financial assistance has been approved by the company's board of directors in a recent meeting [2][7]. Subsidiary Information - Aikewei Biotechnology has a registered capital of 12.31 million yuan and operates in various medical and biotechnology sectors [2]. - As of December 31, 2024, Aikewei's total assets were 672.92 million yuan, with total liabilities of 317.22 million yuan, resulting in a debt-to-asset ratio of 47.14% [3]. - The company reported a net profit loss of 7.48 million yuan for the year 2024 [3]. Related Party Transactions - The shareholder of Aikewei, Jinan High-tech Financial Investment Co., Ltd., is an affiliate of the company, and the financial assistance complies with relevant regulations [2][6]. - The company has not provided any financial assistance to Aikewei in the past 12 months, indicating no overdue financial assistance [7]. Board of Directors' Opinion - The board believes that providing financial assistance to Aikewei is beneficial for its operational needs and aligns with the company's overall strategy, ensuring that risks are manageable and compliant with legal regulations [7].

Group 1 - The board of directors of Shandong Weiming Bio-Pharmaceutical Co., Ltd. held its third meeting of the sixth session on July 25, 2025, with all 11 directors participating [1][2] - The board approved a financial assistance proposal to its controlling subsidiary Sichuan Gukang Pharmaceutical Co., Ltd., allowing a loan of up to 55 million RMB at an interest rate of 1.3% per annum, with a maximum term of one year [1][2] - The financial assistance does not constitute a related party transaction or a major asset restructuring, and it is deemed beneficial for Gukang Pharmaceutical's operational development [2][3] Group 2 - The board approved changes to the management structure of its wholly-owned subsidiary Xiamen Weiming Bio-Pharmaceutical Co., Ltd., appointing Chen Xing as the new legal representative and general manager, and restructuring the governance to a board of directors [1][3] - The changes at Xiamen Weiming do not require shareholder approval and will be finalized upon approval from market supervision authorities [3] - The board also approved an expansion of the business scope for its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd., which will now include various technical services and pharmaceutical production activities [4]

Core Viewpoint - The company is providing financial assistance to its associate company, Jiangxi Huadian Jiujiang Distributed Energy Co., Ltd., in the form of a shareholder loan amounting to 64.827 million RMB, with a term of three years and an interest rate of 3% [2][3][11] Financial Assistance Overview - The financial assistance involves a loan of 64.827 million RMB to Jiangxi Huadian Jiujiang Company, aimed at meeting its operational and developmental funding needs [3] - The loan was approved by the company's board with unanimous support and does not require shareholder meeting approval, thus not constituting a related party transaction [2][3] - Other shareholders of Jiangxi Huadian Jiujiang Company are also providing loans under the same conditions, ensuring no infringement on the company's interests [2][3] Company and Financial Details - Jiangxi Huadian Jiujiang Company was established on March 25, 2011, and focuses on investment in distributed energy projects in Jiujiang City [5][6] - The company has a registered capital of 92.61 million RMB and is primarily engaged in natural gas power generation [5][6] - The financial assistance will be funded from the company's own resources and will not affect its normal business operations [3][11] Risk Control Measures - The company has appointed directors and financial personnel to monitor the operational and loan risks of Jiangxi Huadian Jiujiang Company [4][11] - In case of adverse developments, the company will take timely measures to ensure loan repayment and mitigate financial risks [4][11] Financial Assistance Agreement - The loan agreement specifies that the funds will be used for debt repayment and business operations, with a repayment structure of monthly interest payments and a lump-sum principal repayment at maturity [10] - The company retains the right to demand corrective actions or additional guarantees in case of borrower default [10] Cumulative Financial Assistance - After this loan, the total financial assistance provided by the company amounts to 2.183 billion RMB, representing 14.03% of the latest audited net assets [12] - The financial assistance to external entities amounts to 64.827 million RMB, which is 0.42% of the latest audited net assets, with no overdue amounts reported [12]

Financial Assistance Overview - The company plans to provide financial assistance of RMB 45 million to its subsidiary, Qingdao Borui Zhiyuan Vibration Technology Co., Ltd., to support its business development and operational needs [1][2] - The loan will have a term of 2 years with an annual interest rate of 2.30% [1][4] Reasons and Impact of Financial Assistance - The financial assistance aims to facilitate the subsidiary's business growth and ensure smooth operational cash flow, promoting synergy between the parent and subsidiary companies [1][2] Risk Management Measures - The company holds a 52.07% indirect stake in Qingdao Borui, allowing it to implement effective risk control over its operations and finances [2][4] - The company will enhance daily management of the subsidiary and monitor its financial health to ensure the safety of funds [2][4] Financial Status of the Subsidiary - Qingdao Borui has total assets of RMB 81.844 million and total liabilities of RMB 57.258 million, resulting in a net asset value of RMB 24.586 million [3] - The asset-liability ratio stands at 69.96% [3] Approval Process for Financial Assistance - The financial assistance has been approved by the company's board of directors and does not require further shareholder approval [4] Sponsor's Verification Opinion - The sponsor, Guojin Securities, confirms that the financial assistance complies with relevant laws and regulations and does not harm the interests of the company or its shareholders [4]

Core Viewpoint - The company plans to provide financial assistance to its subsidiaries, Hangzhou Xinshi Semiconductor Co., Ltd. and Chengdu Taitan Testing Technology Co., Ltd., through loans totaling up to 2 billion RMB and 1 billion RMB respectively, to support their business expansion and daily operations [1][2][3] Financial Assistance Overview - The financial assistance will be provided in the form of credit loans without collateral, with a maximum loan amount of 20 million RMB to Hangzhou Xinshi and 10 million RMB to Chengdu Taitan [1][2] - The loan term will not exceed three years from the date of the shareholders' meeting resolution, and the loan amounts can be reused within the term based on actual business needs [1][2][3] Loan Terms - The interest rate will be set at the prevailing Loan Prime Rate (LPR) plus 20 basis points, with interest calculated based on the actual number of days the loan is utilized [2][3] Approval Process - The financial assistance has been approved by the company's board of directors and is pending approval from the shareholders' meeting [2][3] Subsidiary Information - Hangzhou Xinshi Semiconductor Co., Ltd. has a registered capital of 40 million RMB, primarily engaged in chip research, design, and sales, with a 60% ownership by the company [4][6] - Chengdu Taitan Testing Technology Co., Ltd. has a registered capital of 20 million RMB, established for equipment research, production, and sales, with a 60% ownership by the company's wholly-owned subsidiary [7][8] Financial Data of Subsidiaries - As of March 31, 2025, Hangzhou Xinshi reported total assets of 1,828.57 million RMB, a revenue of 1.4 million RMB, and a net loss of 12.29 million RMB [4][6] - Chengdu Taitan reported total assets of 75.41 million RMB, a revenue of 637.25 million RMB, and a net loss of 5.76 million RMB as of March 31, 2025 [8] Risk Management - The company maintains effective control over the use of the financial assistance, ensuring that the funds are utilized appropriately and that risks are manageable [6][9] - The total amount of financial assistance provided after this transaction will be 412.94 million RMB, representing 17.12% of the company's latest audited net assets [10]

Core Viewpoint - The company, Shenzhen Baiwei Storage Technology Co., Ltd., is providing financial assistance to its controlling subsidiaries, aiming to support their business expansion and daily operational funding needs while ensuring that the company's normal operations are not affected [2][3][6]. Financial Assistance Overview - The company plans to lend up to 200 million RMB to its subsidiary Hangzhou Xinshi Semiconductor Co., Ltd. and up to 100 million RMB to Chengdu Taitan Testing Technology Co., Ltd. The loans will be for a maximum period of three years and will be based on actual business needs [2][3]. - The loans are unsecured and will be used for business expansion and daily operational funding [2][5]. Approval Process - The financial assistance has been approved by the company's board of directors and is pending approval from the shareholders' meeting [3][7]. - The financial assistance does not violate any regulations regarding the provision of financial support [3][7]. Subsidiary Information - Hangzhou Xinshi Semiconductor Co., Ltd. has a registered capital of 40 million RMB and is primarily engaged in chip research, design, and sales. The company holds a 60% stake in it [3][4]. - Chengdu Taitan Testing Technology Co., Ltd. has a registered capital of 20 million RMB and focuses on equipment research, production, and sales. The company also holds a 60% stake in this subsidiary [4][5]. Financial Data of Subsidiaries - Hangzhou Xinshi reported total assets of 13.52 million RMB and a net loss of 1.23 million RMB as of March 31, 2025 [4]. - Chengdu Taitan reported total assets of 75.41 million RMB and a net asset of 15.19 million RMB as of March 31, 2025 [4]. Risk Management - The company maintains effective control over its subsidiaries, ensuring that the financial assistance does not pose risks to the company's overall financial health [6][7]. - The total financial assistance provided by the company, including this round, will amount to 412.94 million RMB, which is 17.12% of the company's latest audited net assets [6][7]. Board Opinion - The board believes that providing financial assistance to the subsidiaries aligns with the company's overall interests and will enhance the efficiency of fund utilization while minimizing financing costs [6][7].